Exicure, Inc. (XCUR) is a Biotechnology company in the Healthcare sector, currently trading at $3.96. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is XCUR = $12 (+203.3% upside).
Valuation: XCUR trades at a trailing Price-to-Earnings (P/E) of -5.3 (S&P 500 average ~25).
Net income is $5M (loss), growing at -154.5%/yr. Net profit margin is 0% (thin). Gross margin is -64.8% (-158.4 pp trend).
Balance sheet: total debt is $176,000 against $4M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 1.19 (adequate). Debt-to-assets is 1.3%. Total assets: $14M.
Analyst outlook: 5 / 6 analysts rate XCUR as buy (83%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 0/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).
